Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2023-04-21 Annual Report
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 Annual Report Summary" of Lingkang Pharmaceutical Group Co., Ltd. It contains detailed financial data for the year 2022, including total assets, net profit, revenue, quarterly financial data, shareholder information, and business overview. The text references the full annual report and audit opinion by an accounting firm, indicating it is a summary extracted from the full annual report. The length of the document (6313 characters) and the presence of comprehensive financial and operational data confirm it is a financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K) as it covers company activity and full financial performance for the fiscal year 2022. FY 2022
2023-04-21 Chinese
中信证券股份有限公司关于灵康药业集团股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities regarding the use of temporarily idle raised funds by Lingkang Pharmaceutical Group Co., Ltd. for cash management. It includes regulatory references, approval details, investment scope, risk control measures, and opinions from independent directors, the supervisory board, and the sponsor institution. The document is not a full financial report but a specialized verification and compliance opinion related to the management of raised funds. It does not contain financial statements or quarterly/yearly financial data. The document length is 2696 characters, which is relatively short and focused on a specific regulatory compliance matter. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or regulatory compliance verifications, excluding full annual or interim reports. Q1 2023
2023-04-21 Chinese
2022年年度审计报告
Regulatory Filings
2023-04-21 Chinese
2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2022 profit distribution plan, specifically stating that no profit distribution or capital reserve conversion to shares will be made. It includes details about the board and supervisory committee meetings approving the plan, references to regulatory guidelines on cash dividends, and notes that the plan will be submitted to the 2022 annual shareholders' meeting for approval. The document is relatively short (1455 characters) and serves as a formal announcement of the profit distribution proposal rather than a full financial report or annual report. It does not contain comprehensive financial statements or detailed analysis but rather communicates a specific corporate action related to dividends and profit distribution. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it announces the dividend decision (in this case, no dividend).
2023-04-21 Chinese
关于预计2023年日常关联交易情况的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding the expected daily related-party transactions for the year 2023. It includes details about the nature of the transactions, the parties involved, pricing policies, and the impact on the company. The document explicitly states that the transactions do not require shareholder meeting approval and focuses on compliance with market principles and company independence. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation of financial results. Instead, it is an announcement about related-party transactions, which is a regulatory disclosure. Given the content and length (2089 characters), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-21 Chinese
关于使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding the use of part of its idle funds for cash management through entrusted financial products. It details the purpose, amount, risk controls, and approvals from the board, independent directors, and supervisory board. The document is a formal disclosure about a financing activity related to cash management and investment of idle funds, not a full financial report or earnings release. It does not contain financial statements or detailed financial results but rather an update on capital usage and risk management. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (2004 characters), but it is not merely an announcement of a report publication; it is the actual announcement of a financing-related activity.
2023-04-21 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.